PriceTargets.com logo

Tectonic Therapeutic - TECX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $77.80
  • Forecasted Upside: 236.65%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 2 Strong Buy Ratings
$23.11 As of 10/5/2026 05:00 PM ET
▲ +0.57 (2.53%)

This chart shows the closing price for TECX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tectonic Therapeutic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TECX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TECX

Analyst Price Target is $77.80
▲ +236.65% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Tectonic Therapeutic in the last 3 months. The average price target is $77.80, with a high forecast of $93.00 and a low forecast of $60.00. The average price target represents a 236.65% upside from the last price of $23.11.

This chart shows the closing price for TECX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Tectonic Therapeutic. This rating has held steady since July 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/10/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/8/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/8/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/7/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2026
  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/5/2026

Latest Recommendations

  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/30/2026OppenheimerReiterated RatingOutperform ➝ Outperform$80.00
9/30/2026TD CowenReiterated RatingBuy ➝ Buy
9/1/2026OppenheimerReiterated RatingOutperform ➝ Outperform
8/18/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
8/7/2026Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$101.00 ➝ $93.00
7/20/2026Zacks ResearchDowngradeHold ➝ Strong Sell
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/26/2026Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/13/2026Stifel NicolausInitiated CoverageBuy$75.00
2/5/2026Lifesci CapitalUpgradeStrong-Buy
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/8/2026Truist FinancialLower TargetBuy ➝ Buy$64.00 ➝ $60.00
10/20/2025Wells Fargo & CompanyInitiated CoverageOverweight$101.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/3/2025OppenheimerInitiated CoverageOutperform$80.00
7/21/2025Truist FinancialInitiated CoverageBuy$64.00
6/11/2025Raymond James FinancialInitiated CoverageOutperform$76.00
6/6/2025Lifesci CapitalInitiated CoverageOutperform$87.00
6/5/2025Lifesci CapitalUpgradeStrong-Buy
5/15/2025MizuhoBoost TargetOutperform ➝ Outperform$51.00 ➝ $85.00
4/21/2025MizuhoInitiated CoverageOutperform$51.00
3/21/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$112.00 ➝ $101.00
1/31/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$79.00 ➝ $112.00
11/20/2024Raymond James FinancialInitiated CoverageOutperform$65.00
11/12/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$55.00 ➝ $79.00
11/11/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$49.00 ➝ $69.00
8/22/2024Wells Fargo & CompanyInitiated CoverageOverweight$55.00
7/24/2024Leerink PartnersUpgradeStrong-Buy
7/24/2024Leerink PartnersInitiated CoverageOutperform$49.00
6/26/2024Piper SandlerInitiated CoverageOverweight$76.00
6/24/2024TD CowenInitiated CoverageBuy
(Data available from 10/6/2021 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/9/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/8/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2026
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2026

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tectonic Therapeutic logo
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $23.11
Low: $21.71
High: $23.32

50 Day Range

MA: $30.06
Low: $22.54
High: $37.71

52 Week Range

Now: $23.11
Low: $14.60
High: $39.53

Volume

312,642 shs

Average Volume

235,091 shs

Market Capitalization

$451.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Tectonic Therapeutic?

The following equities research analysts have issued research reports on Tectonic Therapeutic in the last year: Lifesci Capital, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Stifel Nicolaus, TD Cowen, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for TECX.

What is the current price target for Tectonic Therapeutic?

0 Wall Street analysts have set twelve-month price targets for Tectonic Therapeutic in the last year. Their average twelve-month price target is $77.80, suggesting a possible upside of 236.7%. Wells Fargo & Company has the highest price target set, predicting TECX will reach $93.00 in the next twelve months. Truist Financial Corporation has the lowest price target set, forecasting a price of $60.00 for Tectonic Therapeutic in the next year.
View the latest price targets for TECX.

What is the current consensus analyst rating for Tectonic Therapeutic?

Tectonic Therapeutic currently has 1 sell rating, 1 hold rating, 5 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TECX.

What other companies compete with Tectonic Therapeutic?

Other companies that are similar to Tectonic Therapeutic include Zenas BioPharma, Novavax, Vir Biotechnology, Nanobiotix and Stoke Therapeutics. Learn More about companies similar to Tectonic Therapeutic.

How do I contact Tectonic Therapeutic's investor relations team?

Tectonic Therapeutic's physical mailing address is 490 Arsenal Way, Suite 200, Watertown, MA. The company's listed phone number is 617-914-8420 and its investor relations email address is [email protected]. The official website for Tectonic Therapeutic is www.tectonictx.com. Learn More about contacing Tectonic Therapeutic investor relations.